Bio Path Is A Biotechnology Company Developing Targeted Therapies For Acute Myeloid Leukemiaaml Lymphomachronic Lymphocytic Leukemiagynecological Cancer And Other Challenging Cancersthe Company S Lead Product Candidateprexigebersenliposomal Grb2 Antisense Formerly Bp1001Is Currently Being Assessed In A Phase 2 Clinical Study In Previously Untreated Aml Patientswho Are Not Eligible For Or Who Have Decided To Forego Intensive Chemotherapy Because Of Their Fragile Healthand In Refractory Relapsed Aml Patientsadditionallybp1001 A Is Being Assessed In A Phase 1 Study In Refractory Relapsed Patients With Solid Tumorsthe Company S Second Product Bp1002Liposomal Bcl 2 Antisenseis Being Evaluated In Phase 1 Trials In Patients With Refractory Relapsed Lymphoma And Aml
